The Institut Mérieux-backed genome engineering platform developer has closed its series E round with commitments from new and existing investors.
Inscripta, a US-based genome engineering technology producer backed by medical technology holding group Institut Mérieux, has raised $150m for the close of its series E round. The round was co-led by investment and financial services group Fidelity and funds and accounts advised by T Rowe Price, with participation from investment bank Morgan Stanley’s Counterpoint Global…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.